1	Hombre	hombre	NCMS000	C0025266#C0086418#C0043210	persona#organismo_vivo	0-6	579_QUEST_clinical_caseMIR	SENT1	-	-
2	de	de	SPS00	C0332285	atributo	7-9	579_QUEST_clinical_caseMIR	SENT1	-	-
3	78	78		-	-	10-12	579_QUEST_clinical_caseMIR	SENT1	-	-
4	años	año	NCMP000	C0439234	calificador	13-17	579_QUEST_clinical_caseMIR	SENT1	-	-
5	con	con	SPS00	C0332287	atributo	18-21	579_QUEST_clinical_caseMIR	SENT1	-	-
6	antecedentes	antecedente	NCMP000	C0332119_1	situación_1	22-34	579_QUEST_clinical_caseMIR	SENT1	-	-
7	de	de	SPS00	C0332119_2	situación_2	35-37	579_QUEST_clinical_caseMIR	SENT1	-	-
8	diabetes	diabetes	NCFN000	C0011860_1	trastorno_1	38-46	579_QUEST_clinical_caseMIR	SENT1	B-Grp_Enfermedad	-
9	mellitus	mellitus	AQ0CN0	C0011860_2	trastorno_2	47-55	579_QUEST_clinical_caseMIR	SENT1	I-Grp_Enfermedad	-
10	tipo	tipo	NCMS000	C0011860_3	trastorno_3	56-60	579_QUEST_clinical_caseMIR	SENT1	B-Calificador	-
11	2	2	Z	C0011860_4	trastorno_4	61-62	579_QUEST_clinical_caseMIR	SENT1	I-Calificador	-
12	en	en	SPS00	C1720294#C0332285	calificador#atributo	63-65	579_QUEST_clinical_caseMIR	SENT1	-	-
13	tratamiento	tratamiento	NCMS000	C1273870#C0087111	procedimiento#régimen/tratamiento	66-77	579_QUEST_clinical_caseMIR	SENT1	-	-
14	con	con	SPS00	C0332287	atributo	78-81	579_QUEST_clinical_caseMIR	SENT1	-	-
15	metformina	metformina	NC00SC0	C0025598	producto#sustancia	82-92	579_QUEST_clinical_caseMIR	SENT1	B-Grp_Medicamento	-
16	y	y	CC	C1706368	calificador	93-94	579_QUEST_clinical_caseMIR	SENT1	-	-
17	vildagliptina	vildagliptina	NC00SC0	C1570906	producto#sustancia	95-108	579_QUEST_clinical_caseMIR	SENT1	B-Grp_Medicamento	-
18	,	,	Fc	-	-	108-109	579_QUEST_clinical_caseMIR	SENT1	-	-
19	con	con	SPS00	C0332287	atributo	110-113	579_QUEST_clinical_caseMIR	SENT1	-	-
20	última	último	AO0FS0	-	-	114-120	579_QUEST_clinical_caseMIR	SENT1	-	-
21	HbA1C	HbA1C		-	-	121-126	579_QUEST_clinical_caseMIR	SENT1	-	-
22	6,8	6.8	Z	-	-	127-130	579_QUEST_clinical_caseMIR	SENT1	-	-
23	%	%	Ft	-	-	130-131	579_QUEST_clinical_caseMIR	SENT1	-	-
24	,	,	Fc	-	-	131-132	579_QUEST_clinical_caseMIR	SENT1	-	-
25	HTA	hta	NC00YL0	-	-	133-136	579_QUEST_clinical_caseMIR	SENT1	B-Grp_Enfermedad	-
26	en	en	SPS00	C1720294#C0332285	calificador#atributo	137-139	579_QUEST_clinical_caseMIR	SENT1	-	-
27	tratamiento	tratamiento	NCMS000	C1273870#C0087111	procedimiento#régimen/tratamiento	140-151	579_QUEST_clinical_caseMIR	SENT1	-	-
28	con	con	SPS00	C0332287	atributo	152-155	579_QUEST_clinical_caseMIR	SENT1	-	-
29	enalapril	enalapril	NC00SC0	C0014025	sustancia	156-165	579_QUEST_clinical_caseMIR	SENT1	B-Grp_Medicamento	-
30	con	con	SPS00	C0332287	atributo	166-169	579_QUEST_clinical_caseMIR	SENT1	-	-
31	buen	bueno	AQ0MS0	C0205170	calificador	170-174	579_QUEST_clinical_caseMIR	SENT1	-	-
32	control	control	NCMS000	C2587213	atributo	175-182	579_QUEST_clinical_caseMIR	SENT1	-	-
33	tensional	tensional	AQ0CS0	-	-	183-192	579_QUEST_clinical_caseMIR	SENT1	-	-
34	y	y	CC	C1706368	calificador	193-194	579_QUEST_clinical_caseMIR	SENT1	-	-
35	dislipemia	dislipemia	NCFS000	-	-	195-205	579_QUEST_clinical_caseMIR	SENT1	B-Grp_Enfermedad	-
36	en	en	SPS00	C1720294#C0332285	calificador#atributo	206-208	579_QUEST_clinical_caseMIR	SENT1	-	-
37	tratamiento	tratamiento	NCMS000	C1273870#C0087111	procedimiento#régimen/tratamiento	209-220	579_QUEST_clinical_caseMIR	SENT1	-	-
38	con	con	SPS00	C0332287	atributo	221-224	579_QUEST_clinical_caseMIR	SENT1	-	-
39	atorvastatina	atorvastatina	NC00SC0	C0286651	producto#sustancia	225-238	579_QUEST_clinical_caseMIR	SENT1	B-Grp_Medicamento	-
40	con	con	SPS00	C0332287	atributo	239-242	579_QUEST_clinical_caseMIR	SENT1	-	-
41	LDL	low-density_lipoprotein_(lipoproteína_de_baja_densidad)	NC00YL0	-	-	243-246	579_QUEST_clinical_caseMIR	SENT1	-	-
42	de	de	SPS00	C0332285	atributo	247-249	579_QUEST_clinical_caseMIR	SENT1	-	-
43	90	90	Z	-	-	250-252	579_QUEST_clinical_caseMIR	SENT1	-	-
44	mg	mg	NCMN000	-	-	253-255	579_QUEST_clinical_caseMIR	SENT1	-	-
45	/	/	Fh	-	-	255-256	579_QUEST_clinical_caseMIR	SENT1	-	-
46	dL	decilitro	NCMN000	C0439241	calificador	256-258	579_QUEST_clinical_caseMIR	SENT1	-	-
47	.	.	Fp	-	-	258-259	579_QUEST_clinical_caseMIR	SENT1	-	-

1	Ingresa	ingresar	VMIP3S0	-	-	260-267	579_QUEST_clinical_caseMIR	SENT2	-	-
2	en	en	SPS00	C1720294#C0332285	calificador#atributo	268-270	579_QUEST_clinical_caseMIR	SENT2	-	-
3	planta	planta	NCFS000	C0032098	organismo	271-277	579_QUEST_clinical_caseMIR	SENT2	-	-
4	de	de	SPS00	C0332285	atributo	278-280	579_QUEST_clinical_caseMIR	SENT2	-	-
5	medicina	medicinar	VMM02S0	C0021782_1	calificador_1	281-289	579_QUEST_clinical_caseMIR	SENT2	-	-
6	interna	interno	NCFS000	C0021782_2	calificador_2	290-297	579_QUEST_clinical_caseMIR	SENT2	-	-
7	por	por	SPS00	C0678226	atributo	298-301	579_QUEST_clinical_caseMIR	SENT2	-	-
8	neumonía	neumonía	NCFS000	C0694549_1	trastorno_1	302-310	579_QUEST_clinical_caseMIR	SENT2	B-Grp_Enfermedad	-
9	adquirida	adquirir	VMP00SF	C0694549_2	trastorno_2	311-320	579_QUEST_clinical_caseMIR	SENT2	-	-
10	en	en	SPS00	C0694549_3	trastorno_3	321-323	579_QUEST_clinical_caseMIR	SENT2	-	-
11	la	lo	PP3FSA00	C0694549_4	trastorno_4	324-326	579_QUEST_clinical_caseMIR	SENT2	-	-
12	comunidad	comunidad	NCFS000	C0694549_5	trastorno_5	327-336	579_QUEST_clinical_caseMIR	SENT2	-	-
13	con	con	SPS00	C0332287	atributo	337-340	579_QUEST_clinical_caseMIR	SENT2	-	-
14	insuficiencia	insuficiencia	NCFS000	C0865850_1	trastorno_1	341-354	579_QUEST_clinical_caseMIR	SENT2	B-Grp_Enfermedad	-
15	respiratoria	respiratorio	AQ0FS0	C0865850_2	trastorno_2	355-367	579_QUEST_clinical_caseMIR	SENT2	B-Estructura_Corporal	-
16	aguda	agudo	AQ0FS0	C0865850_3	trastorno_3	368-373	579_QUEST_clinical_caseMIR	SENT2	B-Calificador	-
17	secundaria	secundario	AQ0FS0	C0175668	calificador	374-384	579_QUEST_clinical_caseMIR	SENT2	-	-
18	.	.	Fp	-	-	384-385	579_QUEST_clinical_caseMIR	SENT2	-	-

1	¿	¿	Fia	-	-	386-387	579_QUEST_clinical_caseMIR	SENT3	-	-
2	Qué	qué	DT0CN0	-	-	387-390	579_QUEST_clinical_caseMIR	SENT3	-	-
3	medicación	medicación	NCFS000	C0013227	sustancia	391-401	579_QUEST_clinical_caseMIR	SENT3	-	-
4	pautaría	pautar	VMIC3S0	-	-	402-410	579_QUEST_clinical_caseMIR	SENT3	-	-
5	para	para	SPS00	C0521125	calificador	411-415	579_QUEST_clinical_caseMIR	SENT3	-	-
6	el	el	DA0MS0	-	-	416-418	579_QUEST_clinical_caseMIR	SENT3	-	-
7	control	control	NCMS000	C2587213	atributo	419-426	579_QUEST_clinical_caseMIR	SENT3	-	-
8	glicémico	glicémico	AQ0MS00	-	-	427-436	579_QUEST_clinical_caseMIR	SENT3	-	-
9	durante	durante	SPS00	C1444752#C0347984	atributo	437-444	579_QUEST_clinical_caseMIR	SENT3	-	-
10	su	su	DP3CS0	-	-	445-447	579_QUEST_clinical_caseMIR	SENT3	-	-
11	hospitalización	hospitalización	NCFS000	-	-	448-463	579_QUEST_clinical_caseMIR	SENT3	-	-
12	?	?	Fit	-	-	463-464	579_QUEST_clinical_caseMIR	SENT3	-	-

